Elsevier

Clinics in Dermatology

Volume 25, Issue 3, May–June 2007, Pages 334-340
Clinics in Dermatology

Evidence-based therapy for cutaneous sarcoidosis

https://doi.org/10.1016/j.clindermatol.2007.03.011Get rights and content

Abstract

Most of treatments for cutaneous sarcoidosis are extensions of the drugs tested for pulmonary sarcoidosis. There are some exceptions. These include drugs given topically and those with high concentrations in the skin. This review will examine the conventional treatments of cutaneous sarcoidosis and focus on the best available evidence to make recommendations on treatment.

Introduction

The treatment of cutaneous sarcoidosis has been usually derived from agents used for pulmonary sarcoidosis. Table 1 lists the agents described as useful for sarcoidosis in general. The purpose of this report is to discuss the individual agents for sarcoidosis in general and for cutaneous disease in particular. The information regarding therapy for sarcoidosis will be as evidence based as possible. Recent evidence-based guidelines for therapy for sarcoidosis have been made.1 The recommendations pointed out, however, provided limited information regarding treatment of cutaneous disease. The limited information about the treatment of extra pulmonary disease has been noted.2

This article will focus on the conventional agents used for sarcoidosis. There has been a recent interest in the use of biologic agents for sarcoidosis, including cutaneous disease.

In another section, Dr Sweiss will discuss some of these newer agents proposed for cutaneous sarcoidosis.

Section snippets

Corticosteroids

Since the original reports of the utility of corticosteroids for sarcoidosis,3 corticosteroids have been the mainstay of therapy for systemic sarcoidosis. Glucocorticoids have been used for cutaneous sarcoidosis. Topical therapy with high-potency fluorinated corticosteroids is commonly used in patients with localized disease. In some cases, the addition of an occlusive dressing to enhance local absorption has proved effective in refractory skin lesions.4 High-dose topical glucocorticoids have

Antimalarials

The antimalarial agents chloroquine and hydroxychloroquine have been used for many years in rheumatologic diseases such as lupus erythematosus and rheumatoid arthritis.24 These drugs have been used in sarcoidosis for over 40 years.25, 26, 27 In a recent evidence-based review of noncorticosteroid treatment of pulmonary sarcoidosis, antimalarials were felt to be possibly useful for treatment.28 The rate of response appears to be higher for cutaneous compared with pulmonary sarcoidosis.26, 29

Methotrexate

Methotrexate has been the most widely studied nonsteroidal therapy for sarcoidosis. It has been shown to steroid sparing in acute pulmonary sarcoidosis.36 It has been reported as useful by several groups for chronic pulmonary,37, 38 ocular,39, 40 and neurologic41 sarcoidosis. It has been recommended as an alternative to corticosteroids for pulmonary disease.28

Several authors have reported on the use of methotrexate for cutaneous disease.37, 42, 43, 44, 45, 46 Fig. 2 summarizes the studies with

Thalidomide

Thalidomide was first used as a hypnotic in the 1950s. It was withdrawn from the market because of its teratogenic effects. It was then approved by the United States Food and Drug Administration for erythema nodosum leprosum. It has been subsequently found useful in the treatment of a wide variety of skin lesions.59, 60 The agent has multiple effects, including the blockade of tumor necrosis factor (TNF). This led to its study in patients with sarcoidosis.61

The response of thalidomide in

Minocycline and other agents

Minocycline has been reported as useful in treating cutaneous sarcoidosis. In 1 report of 12 patients with chronic cutaneous sarcoidosis treated with 200 mg a day of minocycline, 8 had complete response and 2 had partial response.69 Two of the patients were switched to doxycycline because of toxicity and had continued response. The mechanism of action is unclear. One possibility is the antibacterial effect, including the activity against Propionibacteria acnes, a putative agent for sarcoidosis.

Conclusions

Several agents have been used successfully for cutaneous sarcoidosis. Most of the evidence for these agents, however, is based on case reports and case series. Many of the recommendations for treatment have been extrapolated from studies of pulmonary sarcoidosis. Despite these limitations, there is sufficient evidence to give guidelines for the treatment of cutaneous sarcoidosis with various agents. These include new agents that are specifically directed against tumor necrosis factor.

References (86)

  • G.F. Webster et al.

    Weekly low-dose methotrexate therapy for cutaneous sarcoidosis

    J Am Acad Dermatol

    (1991)
  • H.H. Roenigk et al.

    Methotrexate guidelines revised

    J Am Acad Dermatol

    (1982)
  • R.P. Baughman et al.

    Thalidomide for chronic sarcoidosis

    Chest

    (2002)
  • M. Carlesimo et al.

    Treatment of cutaneous and pulmonary sarcoidosis with thalidomide

    J Am Acad Dermatol

    (1995)
  • J.B. Lee et al.

    Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report

    J Am Acad Dermatol

    (1998)
  • Y.T. Nguyen et al.

    Treatment of cutaneous sarcoidosis with thalidomide

    J Am Acad Dermatol

    (2004)
  • S.J. Oliver et al.

    Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement

    Clin Immunol

    (2002)
  • R.S. Kalish et al.

    Minocycline inhibits antigen processing for presentation to human T cells: additive inhibition with chloroquine at therapeutic concentrations

    Clin Immunol

    (2004)
  • J.D. Doty et al.

    Treatment of sarcoidosis with infliximab

    Chest

    (2005)
  • L. Mallbris et al.

    Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy

    J Am Acad Dermatol

    (2003)
  • J.P. Utz et al.

    Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis

    Chest

    (2003)
  • R.P. Baughman et al.

    Etanercept for refractory sarcoidosis: results of a double blind randomized trial

    Chest

    (2005)
  • R.P. Baughman et al.

    Evidence-based approach to the treatment of sarcoidosis

  • G.W. Hunninghake et al.

    ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders

    Sarcoidosis Vasc Diffuse Lung Dis

    (1999)
  • L.E. Siltzbach

    Effects of cortisone in sarcoidosis: a study of thirteen patients

    Am J Med

    (1952)
  • G. Volden

    Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing

    Acta Derm Venereol

    (1992)
  • A.A. Fisher

    Sarcoid-like periocular dermatitis due to strong topical corticosteroids: prompt response to treatment with tetracycline

    Cutis

    (1987)
  • J. Verbov

    The place of intralesional steroid therapy in dermatology

    Br J Dermatol

    (1976)
  • N.S. Paramothayan et al.

    Corticosteroids for pulmonary sarcoidosis

    Cochrane Database Syst Rev

    (2005)
  • E. Neville et al.

    Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients

    Q J Med

    (1983)
  • R.P. Baughman et al.

    Presenting characteristics as predictors of duration of treatment in sarcoidosis

    QJM

    (2006)
  • G. Rizzato et al.

    The late follow-up of chronic sarcoid patients previously treated with corticosteroids

    Sarcoidosis

    (1998)
  • R.P. Baughman et al.

    Use of fluticasone in acute symptomatic pulmonary sarcoidosis

    Sarcoidosis Vasc Diffuse Lung Dis

    (2002)
  • C.E. Cox et al.

    The sarcoidosis health questionnaire. A new measure of health-related quality of life

    Am J Respir Crit Care Med

    (2003)
  • G. Rizzato et al.

    Prednisone-induced bone loss in sarcoidosis: a risk especially frequent in postmenopausal women

    Sarcoidosis

    (1988)
  • G. Rizzato

    Clinical impact of bone and calcium metabolism changes in sarcoidosis

    Thorax

    (1998)
  • R.A. Adler et al.

    Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs

    Arch Intern Med

    (2003)
  • G. Rizzato et al.

    Nephrolithiasis as a presenting feature of chronic sarcoidosis

    Thorax

    (1995)
  • G. Rizzato et al.

    Reversibility of exogenous corticosteroid-induced bone loss

    Eur J Respir

    (1993)
  • S.J. Gallacher et al.

    Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study

    Thorax

    (1992)
  • S. Gonnelli et al.

    Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients

    Calcif Tissue Int

    (1997)
  • L. Montemurro et al.

    Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients

    Calcif Tissue Int

    (1991)
  • J.G. Hirsch

    Experimental treatment with chloroquine

    Am Rev Respir Dis

    (1961)
  • Cited by (72)

    View all citing articles on Scopus
    View full text